p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.
about
Aurora kinases as targets in drug-resistant neuroblastoma cellsABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertibThe MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastomaCinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigens.Neuroblastoma treatment in the post-genomic era.Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.Cellular Homeostasis and Antioxidant Response in Epithelial HT29 Cells on Titania Nanotube Arrays Surface.MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma.Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance.Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status.Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen.Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma.The long non-coding RNA GAS5 differentially regulates cell cycle arrest and apoptosis through activation of BRCA1 and p53 in human neuroblastoma.MCPIP1 Exogenous Overexpression Inhibits Pathways Regulating MYCN Oncoprotein Stability in Neuroblastoma.Editorial: Targeting MYCN in Pediatric Cancers.Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs.
P2860
Q28543446-A7E62EF3-2464-42D5-91E6-7599B854C8E5Q35790720-AEE89A1C-C97C-4E4E-85D9-1F1EB6921B92Q36692848-5F1B27D2-3820-4F93-93D2-DB638526C48EQ37085969-9A1FB5DD-5289-45F6-95B3-FB9D26C2FEF1Q37633731-20E06805-89F2-491B-AAB2-408C9F24B64AQ37696208-F35794CC-B41F-4CFA-9A3C-43900A884B78Q37700003-C4AB7946-AF7C-4DE5-A358-CD654EAC87DCQ38697986-466C05B8-7633-4482-BB7E-F5C96D61E468Q38741378-CC35F15F-1BF0-4525-888D-A56FC8F19B41Q38890690-7F624155-2AC7-48BF-B3B2-DC06AD9D229AQ38902467-E89825D9-5324-4A83-AB6A-C92F3FC83CAFQ38913917-47540611-ADDD-44E3-ADCD-4561178E218DQ38985584-119CA27C-72DF-4680-B38C-7D76347A2440Q39051757-58E304B4-C867-4871-8748-E48450A9A2F0Q39116011-EAE98393-DA6E-42F1-87F8-9F649F9047C8Q40606235-5ECE119E-F600-462C-9436-A6DE8F201030Q41869723-0FA54FB0-1281-4F49-81D1-C791EA8749C5
P2860
p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.
@en
p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.
@nl
type
label
p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.
@en
p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.
@nl
prefLabel
p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.
@en
p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.
@nl
P2860
P356
P1476
p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.
@en
P2093
Deborah A Tweddle
Lindi Chen
P2860
P356
10.3389/FONC.2012.00173
P577
2012-11-28T00:00:00Z